Suppr超能文献

高流量鼻导管和无创机械通气在小儿哮喘发作中的应用:重症监护中的两年前瞻性观察研究。

High-flow nasal cannula and non-invasive mechanical ventilation in pediatric asthma exacerbation: two-year prospective observational study in intensive care.

机构信息

Pediatric Critical Care Unit, Hospital Infantil Universitario Niño Jesús, Madrid, Spain.

出版信息

Bol Med Hosp Infant Mex. 2023;80(6):355-360. doi: 10.24875/BMHIM.23000070.

Abstract

BACKGROUND

Asthma is a common cause of admission to the pediatric intensive care unit (PICU). We described and analyzed the therapies applied to children admitted to a tertiary PICU because of asthma. Later, we evaluated high-flow nasal cannula (HFNC) use in these patients and compared their evolution and complications with those who received non-invasive ventilation.

METHODS

We conducted a prospective observational study (October 2017-October 2019). Collected data: epidemiological, clinical, respiratory support therapy needed, complementary tests, and PICU and hospital stay. Patients were divided into three groups: (1) only HFNC; (2) HFNC and non-invasive mechanical ventilation (NIMV); and (3) only NIMV.

RESULTS

Seventy-six patients were included (39 female). The median age was 2 years and 1 month. The median pulmonary score was 5. The median PICU stay was 3 days, and the hospital stay was 6 days. Children with HNFC only (56/76) had fewer PICU days (p = 0.025) and did not require NIMV (6/76). Children with HFNC had a higher oxygen saturation/fraction of inspired oxygen ratio ratio (p = 0.025) and lower PCO (p = 0.032). In the group receiving both therapies (14/76), NIMV was used first in all cases. No epidemiologic or clinical differences were found among groups.

CONCLUSION

HFNC was a safe approach that did not increase the number of PICU or hospital days. On admission, normal initial blood gases and the absence of high oxygen requirements were useful in selecting responders to HFNC. Further randomized and multicenter clinical trials are needed to verify these data.

摘要

背景

哮喘是小儿重症监护病房(PICU)收治的常见原因。我们描述并分析了因哮喘收治于三级 PICU 的患儿所接受的治疗。之后,我们评估了高流量鼻导管(HFNC)在这些患者中的应用,并比较了其与接受无创通气患者的演变和并发症。

方法

我们进行了一项前瞻性观察研究(2017 年 10 月至 2019 年 10 月)。收集的数据包括:流行病学、临床、所需呼吸支持治疗、补充检查以及 PICU 和住院时间。患者分为三组:(1)仅 HFNC;(2)HFNC 和无创机械通气(NIMV);(3)仅 NIMV。

结果

共纳入 76 例患者(39 例女性)。中位年龄为 2 岁 1 个月。中位肺部评分 5 分。中位 PICU 住院时间 3 天,住院时间 6 天。仅接受 HFNC(56/76)的患儿 PICU 住院时间更少(p = 0.025),且无需接受 NIMV(6/76)。HFNC 组患儿的氧饱和度/吸入氧分数比值更高(p = 0.025),PCO2 更低(p = 0.032)。同时接受两种治疗的患儿(14/76),所有患儿均首先使用 NIMV。三组间未发现流行病学或临床差异。

结论

HFNC 是一种安全的方法,不会增加 PICU 或住院时间。入院时,正常的初始血气和无高氧需求有助于选择 HFNC 治疗的反应者。需要进一步进行随机、多中心临床试验来验证这些数据。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验